T

TCR2 Therapeutics Inc
F:2K7

Watchlist Manager
TCR2 Therapeutics Inc
F:2K7
Watchlist
Price: 1.442 EUR 3.07% Market Closed
Market Cap: 56.6m EUR

Intrinsic Value

There is not enough data to reliably calculate the intrinsic value of 2K7.

The Intrinsic Value is calculated as the average of DCF and Relative values:

2K7 Intrinsic Value
Not Available
T
Base Case Scenario
Compare 2K7 to

Fundamental Analysis

TCR2 Therapeutics Inc
F:2K7
US
Biotechnology
Market Cap
56.6m EUR
IPO
Feb 14, 2019
US
Biotechnology
Market Cap
56.6m EUR
IPO
Feb 14, 2019
Price
€false
EPS
$false
Company Overview
Loading...
Management
Loading...
Contacts
Loading...
How do you feel about 2K7?
Bearish
Neutral
Bullish
AI Assistant
AI Assistant
Ask me anything about TCR2 Therapeutics Inc
Financials
Annual
Quarterly
TTM

Balance Sheet Decomposition
TCR2 Therapeutics Inc

Current Assets 140.5m
Cash & Short-Term Investments 110.3m
Other Current Assets 30.2m
Non-Current Assets 11m
PP&E 9.2m
Other Non-Current Assets 1.9m
Efficiency

Free Cash Flow Analysis
TCR2 Therapeutics Inc

Last Value
3-Years Average
FCF Margin
Conversion Rate

Earnings Waterfall
TCR2 Therapeutics Inc

Revenue
0 USD
Operating Expenses
-131.4m USD
Operating Income
-131.4m USD
Other Expenses
-31.7m USD
Net Income
-163.1m USD
Fundamental Scores

2K7 Profitability Score
Profitability Due Diligence

TCR2 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

Low 3Y Average Gross Margin
Low 3Y Average Net Margin
Low 3Y Average Operating Margin
Declining ROE
21/100
Profitability
Score

TCR2 Therapeutics Inc's profitability score is 21/100. The higher the profitability score, the more profitable the company is.

2K7 Solvency Score
Solvency Due Diligence

TCR2 Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Low D/E
Long-Term Solvency
Short-Term Solvency
Low Altman Z-Score
56/100
Solvency
Score

TCR2 Therapeutics Inc's solvency score is 56/100. The higher the solvency score, the more solvent the company is.

Wall St
Price Targets

2K7 Price Targets Summary
TCR2 Therapeutics Inc

There are no price targets for 2K7.
Lowest
Price Target
Not Available
Average
Price Target
Not Available
Highest
Price Target
Not Available
View Analyst Estimates
View Analyst Estimates

Dividends

Dividend Yield
Lowest
Average
Highest
Dividend Per Share
N/A
Growth 3Y
Growth 5Y
Growth 10Y
Dividend Safety Score
Very
Unsafe
Unsafe
Safe
Very
Safe
0
25
50
75
100
Shareholder Yield

Current shareholder yield for 2K7 is .

Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?

Shareholder Yield
Dividend Yield
Lowest
Average
Highest
Buyback Yield
Lowest
Average
Highest
Debt Paydown Yield
Lowest
Average
Highest

Competitive Landscape

Company Market Cap Intrinsic Valuation Profitability Solvency Price Change
1Y 3Y 5Y